诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 09-04 16:00:00 EDT

46.60

-0.91

-1.92%

盘后46.50

-0.10-0.21%

19:59 EDT

最高46.74	最低46.04	成交量621.92万
今开46.35	昨收47.51	日振幅1.47%
总市值2,061亿	流通市值1,486亿	总股本44.23亿
成交额2.89亿	换手率0.20%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":46.6,"timestamp":1788552000000,"preClose":47.51,"halted":0,"volume":6219243,"hourTrading":{"tag":"盘后","latestPrice":46.5,"preClose":46.6,"latestTime":"19:59 EDT","volume":155721,"amount":7265196.9882,"timestamp":1788566382364,"change":-0.1,"changeRate":-0.002146,"amplitude":0.009013},"delay":0,"changeRate":-0.01915386234476945,"floatShares":3187922885,"shares":4423075124,"eps":4.003044,"marketStatus":"休市中","change":-0.91,"latestTime":"09-04 16:00:00 EDT","open":46.35,"high":46.74,"low":46.0417,"amount":289192666.29965097,"amplitude":0.014698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.003044,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":47.51,"dividendRate":0.036951,"preHourTrading":{"tag":"盘前","latestPrice":46.34,"preClose":47.51,"latestTime":"09:29 EDT","volume":246725,"amount":11491395.99735,"timestamp":1788528599999,"change":-1.17,"changeRate":-0.024626,"amplitude":0.012208},"postHourTrading":{"tag":"盘后","latestPrice":46.5,"preClose":46.6,"latestTime":"19:59 EDT","volume":155721,"amount":7265196.9882,"timestamp":1788566382364,"change":-0.1,"changeRate":-0.002146,"amplitude":0.009013},"volumeRatio":0.6499981490436224,"impliedVol":0.3694,"impliedVolPercentile":0.119},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"1179367080","title":"异动解读｜诺和诺德盘中下跌3.01%，下一代减肥药试验效果不及礼来Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=1179367080","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179367080?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:59","pubTimestamp":1788530352,"startTime":"0","endTime":"0","summary":"9月4日，诺和诺德盘中下跌3.01%，报46.09美元/股，成交额6376.26万美元。消息面上，诺和诺德下一代减肥药在临床试验中效果不及礼来Zepbound，盘前一度暴跌13%，构成本轮下行核心催化。此前诺和诺德面临多重压力：7月底IL-6单抗III期研究未达主要终点致股价大跌近10%，市场对其\"减肥药依赖症\"担忧持续加剧。与此同时，礼来凭借Zepbound及更丰富的下一代减重药管线实现反超，诺和诺德先发优势被进一步削弱。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德大跌，新一代减肥药疗效不及礼来","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155236227","title":"异动解读｜诺和诺德盘中上涨3.08%，口服减重药中国上市申请获受理催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1155236227","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155236227?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:39","pubTimestamp":1788356395,"startTime":"0","endTime":"0","summary":"9月2日，诺和诺德盘中上涨3.08%，报46.59美元/股，成交额5636.18万美元。消息面上，中国国家药监局药品审评中心已正式受理诺和诺德递交的诺和盈片剂用于长期体重管理的上市申请。临床数据显示25mg剂量64周平均减重可达16.6%，效果对标注射剂型。中国成年超重及肥胖人群约5.4至5.6亿人，GLP-1减重药渗透率仅约2.5%，市场空间广阔。同期，诺和诺德还启动了口服司美格鲁肽低剂量临床研究，进一步拓展适用人群。制药行业整体表现积极，强生涨3.38%、礼来涨1.91%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德上涨，口服减重药国内上市获受理","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663553005","title":"减重用司美格鲁肽片上市申请获受理 口服减重药战火燃至中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2663553005","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663553005?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:52","pubTimestamp":1788180758,"startTime":"0","endTime":"0","summary":"口服减重药物的“战火”正蔓延至中国市场。据诺和诺德方面消息，8月27日，公司递交的诺和盈片剂（司美格鲁肽片）用于长期体重管理的上市申请，已正式获得受理。在此之前，这款药物已经在美国市场展现出其商业潜力——自2026年1月上市以来，累计处方量迅速突破500万张，仅上半年即贡献销售额8.55亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860303596.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860303596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","SGXZ99366536.SGD","LU2106854487.HKD","XLV","IE00B4JS1V06.HKD","LLYZ","LU1023059063.AUD","LU2471134952.CNY","LU2896262040.SGD","SG9999018857.SGD","LU2750360641.GBP","SG9999001176.USD","LU2756315318.SGD","LU2357305700.SGD","LU2236285917.USD","LU2746668461.USD","LU2360106947.USD","LU2361045086.USD","LU2168564495.EUR","IE00BJJMRX11.SGD","LU2462591350.SGD","BK4516","IE0005OL40V9.USD","LU0889565916.HKD","LLYX","LU0456855351.SGD","LU0672654240.SGD","SG9999015986.USD","LU2756315664.SGD","LU2468319806.SGD","IYH","SG9999015945.SGD","IE00BFTCPJ56.SGD","BK4588","LU1623119135.USD","SG9999018865.SGD","IE0001KFT4U8.USD","LU0820561909.HKD","LU1064131342.USD","LU1551013425.SGD","LU1069344957.HKD","SG9999015952.SGD","IE00BFSS7M15.SGD","LU2552382132.HKD","TMED","LU1988902786.USD","LU0823434583.USD","LU0640476718.USD","LU2089283258.USD","FHLC","IE00BZ1G4Q59.USD","LU0683600562.USD","CURE","LU0256863902.USD","LU0106261372.USD","LU0316494557.USD","LU0354030511.USD","LU0471298777.SGD","LU0964807845.USD","LU1548497426.USD","IE00B775H168.HKD","LU2471134879.HKD","LU0006306889.USD","LU0174119429.USD","BK4585","LU0943347566.SGD","LU1720051017.SGD","IE00BKPKM429.USD","LU2213496289.HKD","WDNA","IE00BJJMRY28.SGD","LU2456880835.USD","NVOC","LU0058720904.USD","LU2211815571.USD","LU2168564149.EUR","IE00BK4W5M84.HKD","LU0061475181.USD","LU0109391861.USD","LU0225283273.USD","LU0238689110.USD","IE00BKVL7J92.USD","LU0385154629.USD","LU1868836591.USD","LU1868836914.USD","IE00BKDWB100.SGD","LU2471134523.USD","LU0786609619.USD","LU2168563687.JPY","SG9999014914.USD","LU0345770308.USD","BK4534","LU1366192091.USD","IE00B7KXQ091.USD","LU1720051108.HKD","LU0689472784.USD","LU0122379950.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0203202063.USD","LU1629891620.HKD","NVO","CANC","BK4599","LU2417539215.USD","LU2264538146.SGD","LU2023250504.SGD","LU2023250330.USD","LU0882574055.USD","FTXH","IE0004445015.USD","LU0210536198.USD","LU2750360997.AUD","BK4532","IE00B1BXHZ80.USD","LU0787776722.HKD","IE00BWXC8680.SGD","MEDX","LU2462157665.USD","LU0432979614.USD","LU2237443549.SGD","LU0096364046.USD","BK4533","IE00B2B36J28.USD","IE00BK4W5L77.USD","LLY","LU0823416689.USD","LU1061106388.HKD","GDOC","LU1551013342.USD","LU1989771016.USD","LU2112291526.USD","LU2491049909.HKD","LU0133085943.USD","OZEM","LU1093756325.SGD","AGNG","LLII","LU2461242641.AUD","LU2602419157.SGD","BK4007","SG9999013999.USD","LU2271345857.HKD","LU1232071149.USD","LU1691799644.USD","SGXZ81514606.USD","LU2168564222.USD","SG9999017495.SGD","SGXZ57979304.SGD","LU0256863811.USD","LU2324357040.USD","NVOH","LU0320765059.SGD","JDOC","LU2237443622.USD","NVOX","LU0345770993.USD","LU1983299246.USD","LU1280957306.USD","LU0094547139.USD","LU2552382215.SGD","LU0198837287.USD","LU0354030438.USD","TRUH","LU0114720955.EUR","LU0471298694.HKD","LU1814569148.SGD","LU0708995401.HKD","LU1868836757.USD","LU2237443895.HKD","LU2168564065.EUR","SG9999001176.SGD","LU0154236417.USD","SG9999014880.SGD","VHT","LU0823434740.USD","THNR","LU1323610961.USD","LU1291159041.SGD","LU0079474960.USD","LU1974910355.USD","IE00BJJMRZ35.SGD","GB00BDT5M118.USD","LU1035775433.USD","LU1093756168.USD","LU0320765992.SGD","ELIS","LU0289739699.SGD","IE0004445239.USD","LU0466842654.USD","LU2237438978.USD","ELIL","IE00B1XK9C88.USD","LU1127390331.HKD","LU1267930730.SGD","BK4581","LU2491050071.SGD","LU2237443978.SGD","SGXZ51526630.SGD","PJP","LU2361044865.SGD","LU1804176565.USD","LU2087625088.SGD","LU2552382058.USD","IXJ","LU1868837300.USD","LU0158827781.USD","LU2237443465.HKD","LU0882574139.USD","LU1868837136.USD","LU0266013472.USD","LU2028103732.USD","LU2111349929.HKD","LU2361044949.HKD","LU2089984988.USD","LU1145028129.USD","IE00BN29S564.USD","IHE","SGXZ31699556.SGD","LU0353189680.USD","SG9999014906.USD","IE0009355771.USD","ILDR","LU0158827948.USD","LU2108987350.USD","PPH","LU2063271972.USD","RXL","SG9999015978.USD","LU2265009873.SGD","LU2491050154.USD","LU0097036916.USD","MEDI","LU0417517546.SGD","HRTS","LU2023251221.USD","LU2237443382.USD","LU1979441026.SGD","IE00BFSS8Q28.SGD","LU0234572021.USD","IE00BJLML261.HKD","LU0820561818.USD","LU1917777945.USD","MHIP","LU2471134796.USD","LU2746668974.SGD","LU0820562030.AUD","SG9999014898.SGD","IE00B4R5TH58.HKD","LU0353189763.USD","LU0323591593.USD","LU1712237335.SGD","LU0203201768.USD","LU1057294990.SGD","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174744220","title":"异动解读｜诺和诺德盘中下跌3.03%，口服Wegovy中国上市申请获受理叠加医疗板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1174744220","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174744220?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:03","pubTimestamp":1787839391,"startTime":"0","endTime":"0","summary":"8月27日，诺和诺德盘中下跌3.03%，报45.76美元/股，成交额1.33亿美元。消息面上，中国国家药品监督管理局已受理诺和诺德口服版减肥药Wegovy用于长期体重管理的上市申请。尽管该进展标志着公司在中国减重市场布局迈出关键一步，但当日医疗保健板块整体走弱，Health Care Select Sector SPDR ETF盘前下跌0.7%，iShares生物科技ETF下跌0.5%。此外，竞争对手礼来口服减重药Foundayo已率先在欧洲获批，且替尔泊肽上半年全球销售额达277亿美元，GLP-1赛道竞争格局持续对诺和诺德估值形成压制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德盘中下挫，口服Wegovy在华申请获受理","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662677565","title":"两大减肥药巨头竞逐中国市场：口服减重版司美格鲁肽国内上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2662677565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662677565?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:41","pubTimestamp":1787812915,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0820561909.HKD","IE00BN29S564.USD","LU1127390331.HKD","LU2491050071.SGD","SG9999001176.USD","LU0432979614.USD","GB00BDT5M118.USD","LU1366192091.USD","LU2746668974.SGD","LU1629891620.HKD","RXL","IHE","ILDR","ELIS","LU1069344957.HKD","IE00B7KXQ091.USD","LU0158827781.USD","IE00BK4W5M84.HKD","LU2089284900.SGD","TRUH","LU0256863902.USD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU1145028129.USD","IE00BKPKM429.USD","CANC","LU0466842654.USD","LU1988902786.USD","LU1979441026.SGD","LU2023250504.SGD","LU0061475181.USD","LU2552382058.USD","LU2602419157.SGD","LU0122379950.USD","SG9999015978.USD","LU2237443895.HKD","LU0889565916.HKD","BK4532","LU2168564149.EUR","LLY","SG9999001176.SGD","LU0672654240.SGD","LU0133085943.USD","LU1868837136.USD","BK4599","XLV","LU2237443382.USD","VHT","LU1691799644.USD","HRTS","LU1989771016.USD","SG9999015945.SGD","LU2462591350.SGD","LU2461242641.AUD","LU2417539215.USD","LU2491049909.HKD","LU2552382215.SGD","PPH","LU0154236417.USD","LU0417517546.SGD","SGXZ51526630.SGD","NVO","IE00BKVL7J92.USD","LU1061106388.HKD","SG9999017495.SGD","LU0323591593.USD","LU2237438978.USD","LU0203201768.USD","LU2028103732.USD","LU2089984988.USD","NVOH","LU2271345857.HKD","LU0238689110.USD","LU2746668461.USD","LU0456855351.SGD","BK4581","LU2756315664.SGD","LU0882574139.USD","IE00B1BXHZ80.USD","LU1804176565.USD","IE0002141913.USD","LU0820562030.AUD","LU2361045086.USD","IE0009355771.USD","LU2471134796.USD","LU0079474960.USD","SG9999015986.USD","IXJ","LU2265009873.SGD","LU2468319806.SGD","LU1814569148.SGD","LU1917777945.USD","LU1057294990.SGD","LU2462157665.USD","BK4533","LU2168564495.EUR","LU2750360997.AUD","SG9999014898.SGD","LU0266013472.USD","IYH","LU2213496289.HKD","LU0006306889.USD","LU0943347566.SGD","LU0114720955.EUR","LU1868837300.USD","LU0234572021.USD","SG9999018865.SGD","IE00BJJMRY28.SGD","LU0210536198.USD","LU0471298777.SGD","AGNG","TMED","LU0174119429.USD","IE00BZ1G4Q59.USD","LU0203202063.USD","LU1712237335.SGD","SGXZ57979304.SGD","LU2896262040.SGD","IE00B1XK9C88.USD","IE00B2B36J28.USD","LU0225283273.USD","LU0640476718.USD","IE00B4JS1V06.HKD","SG9999014880.SGD","BK4516","IE0004445015.USD","LU1551013425.SGD","LU1023059063.AUD","LU2357305700.SGD","LU1323610961.USD","LU2112291526.USD","IE00BWXC8680.SGD","LU2324357040.USD","LU0708995401.HKD","MEDI","IE00BFTCPJ56.SGD","LLYZ","LU0471298694.HKD","IE00BFSS8Q28.SGD","LU0256863811.USD","LU2471134879.HKD","LU1974910355.USD","IE00B775H168.HKD","LU0353189763.USD","LU2491050154.USD","LU0345770993.USD","LU0109394709.USD","CURE","ELIL","LU0320765059.SGD","LU2063271972.USD","SG9999014914.USD","LU0058720904.USD","LU2361044949.HKD","LLYX","LU0316494557.USD","SGXZ81514606.USD","BK4588","IE00BKDWB100.SGD","LU2237443622.USD","OZEM","IE00BJJMRX11.SGD","LU2211815571.USD","LU1267930730.SGD","SG9999018857.SGD","LU1868836914.USD","LU2023251221.USD","LU1720051108.HKD","LU2106854487.HKD","MHIP","BK4534","LU2237443978.SGD","LU1064131342.USD","LU2089283258.USD","SGXZ99366536.SGD","LU0353189680.USD","LU2456880835.USD","BK4007","LU0096364046.USD","LU1868836757.USD","LU2471134952.CNY","LU2108987350.USD","BK4585","SG9999013999.USD","LU2750360641.GBP","WDNA","LU1623119135.USD","LU0964807845.USD","LU0820561818.USD","LU2552382132.HKD","LU2471134523.USD","LU0097036916.USD","LU1280957306.USD","LU0094547139.USD","LU1232071149.USD","IE0001KFT4U8.USD","LU1035775433.USD","NVOC","LU0158827948.USD","LU0198837287.USD","LU0109391861.USD","LU0823434740.USD","SG9999014906.USD","LU2264538146.SGD","LU2168564065.EUR","IE0005OL40V9.USD","LU0354030511.USD","LU2361044865.SGD","LU1291159041.SGD","LU0345770308.USD","LU0882574055.USD","LU1868836591.USD","LU2236285917.USD","LU0683600562.USD","FTXH","IE00BK4W5L77.USD","LU1093756325.SGD","SGXZ31699556.SGD","GDOC","IE00BFSS7M15.SGD","THNR","PJP","LU0786609619.USD","LU2756315318.SGD","LU2237443549.SGD","LU0689472784.USD","IE0004445239.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1983299246.USD","NVOX","FHLC","LU0787776722.HKD","LU2360106947.USD","LU1548497426.USD","LU2087625088.SGD","LU0385154629.USD","JDOC","LU1720051017.SGD","LU0823434583.USD","LU2168564222.USD","LU0320765992.SGD","SG9999015952.SGD","LU2237443465.HKD","LLII","LU1551013342.USD","LU2023250330.USD","LU0289739699.SGD","LU0354030438.USD","LU2168563687.JPY","LU1093756168.USD","LU2111349929.HKD","MEDX","IE00BJLML261.HKD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662972248","title":"诺和诺德(NVO.US)：已申请口服Wegovy用于体重管理的批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662972248","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662972248?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:33","pubTimestamp":1787801626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","NVOX","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","LU0154236417.USD","OZEM","THNR","NVOH","BK4585","IE00BZ1G4Q59.USD","NVOC","LU1093756168.USD","BK4007","BK4599","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662695722","title":"诺和诺德于中国递交司美格鲁肽片片剂用于长期体重管理的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2662695722","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662695722?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:19","pubTimestamp":1787800791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","NVO","BK4532","LU1093756168.USD","NVOH","BK4588","THNR","PPH","LU1093756325.SGD","BK4007","OZEM","NVOC","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","NVOX","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164431633","title":"异动解读｜诺和诺德盘中下跌3.01%，报47.195美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164431633","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164431633?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:35","pubTimestamp":1787758512,"startTime":"0","endTime":"0","summary":"8月26日，诺和诺德盘中下跌3.01%，报47.195美元/股，成交额1.8亿美元。诺和诺德所在的制药行业中，个股普遍承压，礼来跌2.64%，强生跌0.94%，默沙东跌1.75%，辉瑞跌1.1%，爵士制药跌1.32%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160853231","title":"异动解读｜诺和诺德盘中上涨3.01%，上半年净利润同比增逾25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160853231","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160853231?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:18","pubTimestamp":1787671121,"startTime":"0","endTime":"0","summary":"8月25日，诺和诺德盘中上涨3.01%，报48.33美元/股，成交额3.31亿美元。消息面上，诺和诺德公布上半年财报，公司实现总营收1753.11亿丹麦克朗（约273.8亿美元），按固定汇率计算同比增长13%；归属于母公司股东的净利润695.46亿丹麦克朗（约108.6亿美元），同比增长25.22%，司美格鲁肽系列产品继续作为核心收入支柱驱动增长。此外，公司近期启动了口服司美格鲁肽低剂量临床研究（OASIS 5），旨在探索更精准的个性化减重方案，进一步拓展其在减重市场的布局。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德盘中上涨，上半年净利增逾25%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737643","title":"大行评级｜小摩：上调诺和诺德目标价至275丹麦克朗，维持“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737643","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662737643?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:07","pubTimestamp":1787663263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0882574139.USD","LU1116320901.HKD","IE00BKDWB100.SGD","LU0048584097.USD","LU0787776722.HKD","THNR","XLF","LU2505996681.GBP","IE00BFXG1179.USD","LU1496350502.SGD","LU1162221912.USD","LU0971096721.USD","LU0154236417.USD","LU0345769631.USD","IE00BK4W5L77.USD","LU0234572021.USD","LU0942090050.USD","LU2430703095.HKD","OZEM","LU0859254822.USD","LU1366192091.USD","IE00B1XK9C88.USD","BK4585","BK4504","LU1064131342.USD","LU1720051017.SGD","IE00B1BXHZ80.USD","LU0820561818.USD","BK4207","LU2023250843.SGD","BK4588","LU1261432733.SGD","LU0820561909.HKD","LU2430703251.USD","JPM","LU0234570918.USD","LU2417539215.USD","IE00BJTD4N35.SGD","LU0417517546.SGD","BK4581","PPH","LU1551013342.USD","IE00BN8TJ469.HKD","LU1145028129.USD","IE000M9KFDE8.USD","LU0683600562.USD","FNCL","LU1551013425.SGD","LU1720051108.HKD","IE00BWXC8680.SGD","LU0211326839.USD","SG9999002224.SGD","LU1670628061.USD","LU2211815571.USD","KBWB","LU1894683264.USD","LU2054465674.USD","LU0640476718.USD","LU2237443382.USD","LU1267930490.SGD","IE00B775SV38.USD","LU2237443465.HKD","LU1093756168.USD","IE00BLSP4239.USD","IE00BZ1G4Q59.USD","TRUF","UYG","LU0310799852.SGD","LU1116320737.USD","LU2236285917.USD","LU1280957306.USD","LU2213496289.HKD","LU1244550577.SGD","VFH","LU1629891620.HKD","LU2746668974.SGD","LU0345770993.USD","LU0203345920.USD","IE00BYXW3230.USD","LU0006306889.USD","BK4532","LU0203347892.USD","LU1244550494.USD","IE0034235295.USD","LU2746668461.USD","IE00BHPRN162.USD","LU0943347566.SGD","LU2237443622.USD","LU1084165304.USD","LU0689472784.USD","LU1244550221.USD","NVO","LU0496365809.HKD","NVOH","BK4534","LU0149725797.USD","IE00BJTD4V19.USD","LU2237443895.HKD","LU0106831901.USD","LU0215105999.USD","LU1974910355.USD","LU2756315318.SGD","LU2264538146.SGD","FTXO","LU2756315664.SGD","LU2242649171.HKD","IE00BBT3K403.USD","LU1670627923.USD","LU2505996509.AUD","LU0208291251.USD","LU0320765646.SGD","LU0345770308.USD","IE00B3S45H60.SGD","LU0211326755.USD","LU0820562030.AUD","LU0868494617.USD","BK4516","LU1894683348.USD","LU0976567544.SGD","BK4007","IXG","LU0256863811.USD","LU2552382058.USD","NVOX","TFNS","IE00BJLML261.HKD","LU0964807845.USD","LU2592432038.USD","LU0251132253.USD","LU1363072403.SGD","LU1914381329.SGD","LU2106854487.HKD","LU0170899867.USD","LU0211331839.USD","LU0187121727.USD","LU1917777945.USD","LU1668664300.SGD","LU1988902786.USD","LU2023250330.USD","LU1032466523.USD","LU2552382132.HKD","LU2357305700.SGD","JPMO","LU0238689110.USD","IE0034235303.USD","LU0868494708.USD","LU2237443549.SGD","LU0265550359.USD","LU1119994496.HKD","IE00BDCRKT87.USD","BK4566","LU0323591593.USD","LU0256863902.USD","BK4550","LU0106261372.USD","LU2237443978.SGD","LU0265550946.USD","SG9999002232.USD","LU0345769128.USD","IYG","NVOC","LU2462157665.USD","LU2552382215.SGD","IE00BKVL7J92.USD","LU2357627491.SGD","LU0211327993.USD","LU1548497426.USD","LU2381873111.SGD","IE00BDRTCR15.USD","BK4533","LU0070302665.USD","IE00BLSP4452.SGD","IE0034235188.USD","LU0267386448.USD","BK4599","LU0211328371.USD","LU1496350171.SGD","LU0320765489.SGD","LU2430703178.SGD","IE00BK4W5M84.HKD","LU1093756325.SGD","IYF","LU2244417387.USD","JPO","LU2023250504.SGD","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773743","title":"诺和诺德上半年营收增长 司美格鲁肽成收入支柱","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773743","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773743?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:57","pubTimestamp":1787662627,"startTime":"0","endTime":"0","summary":"丹麦制药巨头诺和诺德（NovoNordisk，NYSE：NVO）近日公布了2026年第二季度及上半年部分关键财务指标。财报显示，今年上半年，诺和诺德实现总营收1753.11亿丹麦克朗（约273.8亿美元），按固定汇率计算同比增长13%；实现归属于母公司股东的净利润695.46亿丹麦克朗（约108.6亿美元），同比增长25.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253853266681.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253853266681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","NVOX","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","LU0154236417.USD","OZEM","THNR","NVOH","BK4585","IE00BZ1G4Q59.USD","NVOC","LU1093756168.USD","BK4007","BK4599","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136022135","title":"异动解读｜诺和诺德盘中上涨3.02%，启动低剂量口服减肥药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136022135","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136022135?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:09","pubTimestamp":1787148581,"startTime":"0","endTime":"0","summary":"8月19日，诺和诺德盘中上涨3.02%，报47.02美元/股，成交额2.1亿美元。消息面上，诺和诺德已于8月12日正式启动一项名为OASIS 5的临床研究，旨在评估口服索玛鲁肽低剂量方案对超重或肥胖患者体重的影响。该研究计划纳入约450名受试者，预计于2028年4月完成，主要终点为确定口服索玛鲁肽治疗超重或肥胖患者的最低有效剂量。此举被视为诺和诺德在口服GLP-1赛道上的进一步布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660418064","title":"据报诺和诺德（NVO）启动低剂量减肥药试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660418064","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660418064?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:38","pubTimestamp":1787132322,"startTime":"0","endTime":"0","summary":"根据美国政府临床试验数据库最新发布的信息，诺和诺德已于8月12日正式启动一项涵盖450名患者的全新临床研究，旨在评估其热门减肥药索玛鲁肽口服制剂的低剂量疗效。随着减重市场的成熟，诺和诺德希望通过该研究确定在帮助患者维持或达成减重目标的前提下，可使用的最低有效剂量，从而为患者提供更为精准、个性化的口服治疗方案。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NzFhNTI4MGUwYzI0YmU3ZWQ0MDcxNDc2MTkyOTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzFhNTI4MGUwYzI0YmU3ZWQ0MDcxNDc2MTkyOTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","NVO","NVOX","OZEM","LU0154236417.USD","BK4599","BK4588","LU1093756168.USD","BK4007","PPH","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446361","title":"诺和诺德(NVO.US)启动低剂量Wegovy口服药临床研究 瞄准更广泛减重人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446361","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660446361?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:50","pubTimestamp":1787129405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","BK4599","LU1093756168.USD","NVOX","BK4585","BK4532","IE00BKVL7J92.USD","OZEM","NVO","BK4007","LU0154236417.USD","LU1093756325.SGD","NVOH","THNR","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448604","title":"据媒体消息，诺和诺德(NVO.US)在一项新的肥胖症研究中，开始测试低剂量Wegovy口服药片。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448604","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660448604?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:31","pubTimestamp":1787124663,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","NVO","BK4007","NVOH","IE00BZ1G4Q59.USD","BK4599","THNR","PPH","BK4585","BK4588","BK4532","LU1093756168.USD","LU1093756325.SGD","OZEM","LU0154236417.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660149850","title":"美股异动｜减肥药概念股逆势上扬，礼来涨2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660149850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660149850?lang=zh_cn&edition=full","pubTime":"2026-08-18 21:54","pubTimestamp":1787061253,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AGNG","LU1280957306.USD","LU0122379950.USD","IE00BWXC8680.SGD","LU1548497426.USD","LU1093756168.USD","IE00BKPKM429.USD","IE0004445239.USD","LU1127390331.HKD","LU0672654240.SGD","LU0114720955.EUR","LU1064131342.USD","SGXZ31699556.SGD","LU0820561818.USD","LU2023250504.SGD","RXL","LU0708995401.HKD","LU0820562030.AUD","LU0943347566.SGD","LU2417539215.USD","LU2108987350.USD","LU2456880835.USD","IHE","LU1023059063.AUD","LU2087625088.SGD","LLYZ","SG9999018865.SGD","WDNA","LU2089283258.USD","LU0158827948.USD","LU2491050071.SGD","SG9999017495.SGD","THNR","LU2552382215.SGD","NVO","LU2361044949.HKD","LU0061475181.USD","LU1323610961.USD","LU0106261372.USD","GB00BDT5M118.USD","LU1061106388.HKD","JDOC","LU2028103732.USD","ELIL","LLII","LU2360106947.USD","TMED","MHIP","LU2471134796.USD","LU1868836914.USD","SG9999015978.USD","ELIS","FTXH","IE00BFTCPJ56.SGD","LU0786609619.USD","IE00BK4W5M84.HKD","LU0256863811.USD","LU0683600562.USD","LU0823434583.USD","IE00BKDWB100.SGD","LU0354030438.USD","LU2237443895.HKD","IE00BFSS7M15.SGD","LU1291159041.SGD","LU0158827781.USD","LU2023251221.USD","LU2361045086.USD","SG9999014906.USD","LU0097036916.USD","LU0198837287.USD","LU2237443382.USD","LU2237443978.SGD","LU0820561909.HKD","LU1623119135.USD","LU0787776722.HKD","LU2462591350.SGD","SGXZ57979304.SGD","LU2237443622.USD","LU0385154629.USD","IE00BJJMRY28.SGD","LU1551013342.USD","BK4532","LU1267930730.SGD","LU2750360641.GBP","LU2491050154.USD","IE0004445015.USD","NVOH","SG9999001176.SGD","SG9999001176.USD","LU0823434740.USD","SG9999014880.SGD","IE00B1XK9C88.USD","LU2023250330.USD","LU0345770993.USD","CANC","LU0964807845.USD","LU2746668461.USD","IXJ","LU2896262040.SGD","LU0466842654.USD","LU2746668974.SGD","LU2750360997.AUD","LU1232071149.USD","GDOC","SGXZ81514606.USD","LU1868836591.USD","LU2168564065.EUR","IE0005OL40V9.USD","LU0109394709.USD","LU2211815571.USD","SG9999014898.SGD","LU0471298694.HKD","BK4585","IE00BJJMRX11.SGD","MEDX","LU2168564495.EUR","LU0203202063.USD","LU1983299246.USD","VHT","LU0289739699.SGD","IE0002141913.USD","HRTS","LU1629891620.HKD","LU0320765059.SGD","LU0096364046.USD","LU0234572021.USD","LU2112291526.USD","LU2552382058.USD","LU0456855351.SGD","IE00BKVL7J92.USD","LU2213496289.HKD","LU1551013425.SGD","LU1979441026.SGD","LU0432979614.USD","XLV","IE00BJT1NW94.SGD","LU2089984988.USD","IE00B4R5TH58.HKD","LU2111349929.HKD","LU0225283273.USD","LU2324357040.USD","LU0094547139.USD","SG9999014914.USD","LU0471298777.SGD","SG9999015952.SGD","LU2237443465.HKD","IE0001KFT4U8.USD","SGXZ99366536.SGD","IE00BFSS8Q28.SGD","LU0238689110.USD","LU0210536198.USD","LU2237438978.USD","IE00BJJMRZ35.SGD","PPH","LU1814569148.SGD","LU2361044865.SGD","LU1712237335.SGD","LU2462157665.USD","LU0823416689.USD","IE00BJLML261.HKD","LU2236285917.USD","LU0889565916.HKD","LU0323591593.USD","LU0689472784.USD","IE00B2B36J28.USD","IE00BN29S564.USD","LU0354030511.USD","BK4581","BK4534","LU2461242641.AUD","SG9999015945.SGD","LU2357305700.SGD","LU1720051108.HKD","LU2471134523.USD","LU2168564222.USD","LU0417517546.SGD","SG9999018857.SGD","IE00B7KXQ091.USD","BK4533","LU0154236417.USD","LU0203201768.USD","LU0109391861.USD","LU0882574139.USD","LU2468319806.SGD","LU2602419157.SGD","LU0006306889.USD","LU1145028129.USD","IE0009355771.USD","BK4007","OZEM","SG9999013999.USD","SGXZ51526630.SGD","LU2264538146.SGD","LU1035775433.USD","LU1720051017.SGD","LU1917777945.USD","LU1093756325.SGD","SG9999015986.USD","LU0174119429.USD","BK4599","ILDR","LU0266013472.USD","LU1974910355.USD","IE00B1BXHZ80.USD","BK4516","LU1868837300.USD","LU0256863902.USD","LU2106854487.HKD","LU2168563687.JPY","LU1366192091.USD","LU0058720904.USD","IE00B4JS1V06.HKD","LU0353189680.USD","LU1868837136.USD","LU0345770308.USD","LU2089284900.SGD","LU1057294990.SGD","LU2168564149.EUR","LU2063271972.USD","LU0882574055.USD","LU1989771016.USD","LU0316494557.USD","LU1804176565.USD","LU2237443549.SGD","LU1069344957.HKD","LU2265009873.SGD","LLYX","BK4588","IE00B775H168.HKD","LU2756315664.SGD","IE00BZ1G4Q59.USD","LU2491049909.HKD","LU0133085943.USD","LLY","LU2552382132.HKD","LU2756315318.SGD","IE00BK4W5L77.USD","NVOX","LU0640476718.USD","LU2271345857.HKD","LU0079474960.USD","LU0353189763.USD","LU1868836757.USD","LU1988902786.USD","LU2471134952.CNY","LU0320765992.SGD","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149711042","title":"异动解读｜诺和诺德盘中下跌3.05%，贝伦贝格下调评级至持有并降目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1149711042","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149711042?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:48","pubTimestamp":1786542534,"startTime":"0","endTime":"0","summary":"8月12日，诺和诺德盘中下跌3.05%，报46.05美元/股，成交额8214.8万美元。消息面上，投行贝伦贝格将诺和诺德评级从\"买入\"下调至\"持有\"，同时将目标价从50美元下调至47美元。据FactSet统计，该股当前分析师平均评级为\"增持\"，平均目标价49.12美元。市场对诺和诺德GLP-1产品增长放缓及与礼来竞争压力加大的担忧持续发酵，叠加投行下调评级与目标价，进一步压制市场情绪。诺和诺德所在的制药行业中，礼来跌0.66%，默沙东涨0.74%，强生跌0.76%，辉瑞跌0.92%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德盘中下跌3.05%，贝伦贝格下调评级至持有并降目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658319970","title":"贝伦贝格降诺和诺德评级至“持有”","url":"https://stock-news.laohu8.com/highlight/detail?id=2658319970","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658319970?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:56","pubTimestamp":1786539374,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","PPH","OZEM","BK4599","THNR","IE00BZ1G4Q59.USD","BK4585","NVOH","LU0154236417.USD","BK4588","NVOX","LU1093756168.USD","BK4532","NVO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162996918","title":"异动解读｜诺和诺德盘前下跌3.05%，贝伦贝格下调目标价至47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162996918","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162996918?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:27","pubTimestamp":1786530424,"startTime":"0","endTime":"0","summary":"8月12日，诺和诺德盘前下跌3.05%，报45.73美元/股，成交额464.7万美元。消息面上，投行贝伦贝格将诺和诺德目标价从50美元下调至47美元，成为近期对该股发出谨慎信号的机构之一。市场对诺和诺德GLP-1产品增长放缓及与礼来竞争压力加大的担忧持续发酵，叠加投行下调目标价，进一步压制盘前情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德盘前下跌3.05%，贝伦贝格下调目标价至47美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658256429","title":"贝伦贝格将诺和诺德目标股价从50美元下调至47美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658256429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658256429?lang=zh_cn&edition=full","pubTime":"2026-08-12 13:05","pubTimestamp":1786511104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","OZEM","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","THNR","NVO","BK4007","NVOX","NVOH","BK4599","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0465},{"period":"3month","weight":0.0847},{"period":"6month","weight":0.2079},{"period":"1year","weight":-0.1699},{"period":"ytd","weight":-0.0841}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018023},{"month":5,"riseRate":0.565217,"avgChangeRate":0.019713},{"month":6,"riseRate":0.695652,"avgChangeRate":0.026728},{"month":7,"riseRate":0.478261,"avgChangeRate":-0.002045},{"month":8,"riseRate":0.521739,"avgChangeRate":0.005204},{"month":9,"riseRate":0.565217,"avgChangeRate":-0.002306},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}